Medra Brasil Medicamentos

Medra is a Brazilian specialty pharmaceutical company focused on the commercialization and distribution of high-complexity medications for rare diseases, oncology, and hematology. The company serves as a strategic partner for international biotechnology firms, providing end-to-end solutions for entering the Brazilian market, including regulatory affairs, market access, and specialized logistics. Medra's portfolio features innovative therapies such as migalastat for Fabry disease and burosumab for X-linked hypophosphatemia. By bridging the gap between global innovation and local patient needs, the company ensures access to life-altering treatments within the Brazilian healthcare system. Medra operates with a high degree of specialization in navigating the complex regulatory environment of ANVISA and the Brazilian public health sector.